Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience
暂无分享,去创建一个
G. Castaman | S. Linari | L. Pieri | P. Tonelli | P. Prosperi | M. Coppo | C. Carulli | M. Attanasio | F. Salvianti | R. Fjerza | F. Demartis
[1] V. Jiménez‐Yuste,et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies , 2022, Blood advances.
[2] B. Nolan,et al. Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.
[3] V. Jiménez‐Yuste,et al. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] G. Kenet,et al. Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] J. Oldenburg,et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with/without FVIII inhibitors from the HAVEN 1-4 studies. , 2020, Blood.
[6] M. Lewandowska,et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] M. Franchini,et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[8] E. Santagostino,et al. WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] R. Butler,et al. Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] E. Santagostino,et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. , 2020, Blood transfusion = Trasfusione del sangue.
[11] J. Oldenburg,et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. , 2019, Blood.
[12] P. Kuebler,et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program , 2019, Journal of thrombosis and haemostasis : JTH.
[13] J. Oldenburg,et al. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A , 2019, Thrombosis and Haemostasis.
[14] C. Hermans,et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. , 2019, The Lancet. Haematology.
[15] J. Oldenburg,et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.
[16] O. Christophe,et al. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? , 2017, Blood.
[17] J. Oldenburg,et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.
[18] Tetsuji Sato,et al. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. , 2016, The New England journal of medicine.
[19] A. Savic,et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[20] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[21] F. Girolami,et al. Identification of seven novel mutations of F8C by DHPLC , 2002, Human mutation.